The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.


Letter to the Editor

Editor, – Professor Ebeling’s article ( Aust Prescr 2011;34:176-81) provided a succinct summary of the current available pharmacological interventions for osteoporosis.

However, with regard to Pharmaceutical Benefits Scheme-listed indications for osteoporosis drugs (Table of the article), alendronate is now indicated for patients (aged 70 or older) with a T-score of –2.5 or less (

Kevin Kwan
Registrar, Geriatric medicine
Nedlands, WA


Author's comments

Professor Peter Ebeling, author of the article, comments:

I thank Dr Kwan for the additional information. This was not available when the article was finalised for publication.

Kevin Kwan

Registrar, Geriatric medicine Nedlands, WA

Professor Peter Ebeling